9-Apr-2026 6:00 AM CST - Business Wire Definium Therapeutics to Participate at Upcoming Investor Conferences and Events Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in the following investor conferences and events: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Thursday, April 16, 2026 at 3:00 PM EDT Webcast
26-Mar-2026 6:00 AM CST - Business Wire Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026. Presentations and live question and answer sessions will be led by members of Definiums executive leadership team and external key opinion leaders who wi
24-Feb-2026 6:01 AM CST - Business Wire Definium Therapeutics to Participate at Upcoming Investor Conferences Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date and Time: Monday, March 2, 2026 at
19-Feb-2026 3:01 PM CST - Business Wire Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates. Listeners
9-Apr-2026 6:00 AM CST - Business Wire Definium Therapeutics to Participate at Upcoming Investor Conferences and Events Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in the following investor conferences and events: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Thursday, April 16, 2026 at 3:00 PM EDT Webcast
26-Mar-2026 6:00 AM CST - Business Wire Definium Therapeutics to Host Investor and Analyst Day in New York on April 22, 2026 Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced additional details for its Investor & Analyst Day in New York on April 22, 2026. Presentations and live question and answer sessions will be led by members of Definiums executive leadership team and external key opinion leaders who wi
24-Feb-2026 6:01 AM CST - Business Wire Definium Therapeutics to Participate at Upcoming Investor Conferences Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Companys management team will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date and Time: Monday, March 2, 2026 at
19-Feb-2026 3:01 PM CST - Business Wire Definium Therapeutics to Report Full Year 2025 Financial Results on February 26, 2026 Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EST on Thursday, February 26, 2026 to report financial results for the full year ended December 31, 2025, and discuss recent business updates. Listeners
